Can a patient with a prior humeral fracture and orthopedic hardware receive a shoulder intra‑articular injection for arthritis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, a patient with prior humeral fracture and hardware can receive a shoulder intra-articular injection for arthritis, but timing and consultation are critical.

Intra-articular therapy (IAT) may be performed after orthopedic hardware placement following consultation with the surgical team 1. This is the key recommendation that directly addresses your scenario.

Key Considerations and Algorithm

Timing Matters

  • Wait at least 3 months after hardware placement before performing the injection 1
  • If the hardware was placed more than 3 months ago, the injection can proceed with appropriate precautions
  • If less than 3 months, defer the injection or consult with the orthopedic surgeon who placed the hardware

Infection Risk with Hardware Present

The presence of orthopedic hardware creates a heightened infection concern:

  • Strict aseptic technique is mandatory 1
  • The infection risk with hardware present is approximately 1.77% versus 0.91% in patients without hardware 2
  • This represents a nearly 2-fold increased risk (OR 1.98) when injecting into a joint with existing hardware 2

Practical Steps Before Proceeding

Consultation requirement:

  • Contact the orthopedic surgeon who placed the hardware to:
    • Confirm adequate healing time has elapsed
    • Rule out any ongoing concerns about hardware stability or infection
    • Document this consultation in the medical record

Patient counseling must include:

  • Informed consent about the slightly elevated infection risk with hardware present 1
  • Signs of infection to monitor (increased pain, warmth, redness, fever)
  • The need for glucose monitoring if diabetic, particularly days 1-3 post-injection 1

Technical considerations:

  • Use ultrasound guidance to improve accuracy and avoid hardware 1
  • Ensure the injection enters the glenohumeral joint space, not soft tissue near hardware
  • Maintain strict sterile technique throughout the procedure 1

Common Pitfalls to Avoid

  1. Don't inject too soon after hardware placement - the 3-month minimum is evidence-based 1
  2. Don't skip the surgical team consultation - this is specifically recommended in guidelines 1
  3. Don't minimize infection risk counseling - patients with hardware have demonstrably higher infection rates 2
  4. Don't proceed if there's any concern about hardware infection or instability - this would be an absolute contraindication

The Evidence Hierarchy

The EULAR guidelines 1 provide Level 3 evidence (Grade C recommendation) with 88% expert agreement that IAT may be performed after orthopedic procedures with surgical team consultation. This guideline recommendation takes precedence and is supported by research showing increased infection risk 2 when hardware is present, reinforcing why the consultation and timing requirements exist.

The fracture itself is not a contraindication once healed, but the hardware creates the clinical concern that requires the algorithmic approach outlined above.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.